Rebimastat is a synthetic, sulfhydryl-based, second-generation matrix metalloproteinase (MMP) inhibitor that was developed as an investigational antineoplastic agent. Designed to target and inhibit specific… Read more
Rebimastat is a synthetic, sulfhydryl-based, second-generation matrix metalloproteinase (MMP) inhibitor that was developed as an investigational antineoplastic agent. Designed to target and inhibit specific zinc-dependent MMPs, such as MMP-1, -2, and -9, the compound functions by blocking enzyme activity to disrupt processes like extracellular matrix degradation, angiogenesis, and tumor metastasis. For pharmaceutical research and development, high-quality reference standards of Rebimastat are essential for accurate analytical testing and rigorous quality control. These products support detailed impurity profiling, allowing for the precise identification of potential degradation products and synthetic impurities that may arise during drug manufacturing. Furthermore, stable isotope labelled compounds in this category serve as critical internal standards for pharmacokinetic studies, ensuring that researchers can reliably quantify drug concentrations and validate analytical methods throughout the drug development lifecycle.